EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use

Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, Michael Lamson, Pippa Loupe, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Kelli R Franzenburg, Eran Harary, Anna Elgart

CNS Drugs · 2026-08 · 40 (8) · 1165-1177

DOI: 10.1007/s40263-026-01302-y ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CNS Drugs, online erschienen am 15.06.2026. Verfasst von Avia Merenlender Wagner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. Avia.MerenlenderWa…. Hauptthemen laut MEDLINE: Risperidone, Antipsychotic Agents, Schizophrenia, Psychotic Disorders. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research and Development, Teva Pharmaceutical Industries, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RisperidoneAntipsychotic AgentsSchizophreniaPsychotic DisordersHumansMaleFemaleAdultInjections, SubcutaneousDelayed-Action PreparationsMiddle AgedDose-Response Relationship, DrugSuspensions

Substanzen

RisperidoneAntipsychotic AgentsDelayed-Action PreparationsSuspensions

Autor:innen und Institutionen

  • Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. Avia.MerenlenderWagner@teva.co.il.
  • Magic Wand Research LLC, Philadelphia, PA, USA.
  • Teva PLIVA Croatia Ltd, Research and Development, Zagreb, Croatia.
  • Nuventra Pharma Sciences, Pharmacokinetics and Clinical Pharmacology, Carrboro, NC, USA.
  • Teva Branded Pharmaceutical Products LLC, West Chester, PA, USA.
  • Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel.

Förderung

  • Research and Development, Teva Pharmaceutical Industries, Ltd.

Zitieren

APA

Merenlender Wagner, A., Perlstein, I., Farkas, P., Lamson, M., Loupe, P., Spiegelstein, O., Kalmanczhelyi, A., Tiver, R., Franzenburg, K. R., Harary, E., & Elgart, A. (2026). A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. CNS Drugs, 40(8), 1165-1177. https://doi.org/10.1007/s40263-026-01302-y

Vancouver

Merenlender Wagner A, Perlstein I, Farkas P, Lamson M, Loupe P, Spiegelstein O, et al. A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. CNS Drugs. 2026;40(8):1165-1177. doi:10.1007/s40263-026-01302-y

BibTeX
@article{MerenlenderWagner2026,
  author = {Merenlender Wagner, Avia and Perlstein, Itay and Farkas, Pavel and Lamson, Michael and Loupe, Pippa and Spiegelstein, Ofer and Kalmanczhelyi, Attila and Tiver, Ryan and Franzenburg, Kelli R and Harary, Eran and Elgart, Anna},
  title = {A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use},
  journal = {CNS Drugs},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {1165--1177},
  doi = {10.1007/s40263-026-01302-y}
}
Kostenlos starten →